Benjamin J Murdock
Research Assistant
Professor
Neurology
Neurology
109 Zina Pitcher Pl, 5019 AAT-BSRB
Ann Arbor, MI 48109
[email protected]

Available to mentor
Benjamin J Murdock
Research Assistant Professor
  • Qualifications
  • Research Overview
  • Recent Publications
    • Qualifications
    • Postdoctoral Research Fellow
      University of Michigan, Neurology, 2015
    • Post Doctoral Research Fellow
      University of Michigan/Ann Arbor Veterans Affairs Healthcare System, Division of Pulmonary and Critical Care Medicine, 2014
    • Postdoctoral Fellow
      University of Michigan, Microbiology and Immunology, 2014
    • PhD, Immunology
      University of Michigan, Ann Arbor, 2010
    • BS, Microbiology, Immunology, and Molecular Genetics
      University of California, Los Angeles, 2003
    Research Overview

    The primary focus of my research is the role of the immune system in driving progression of amyotrophic lateral sclerosis (ALS). This research has two main branches: 1) an investigation into the use of JAK/STAT inhibitors to suppress NK cell-mediated neuronal damage and 2) an investigation into the impact of patient demographics on immunity in ALS and its potential for therapeutic treatment.

    Recent Publications See All Publications
    • Journal Article
      Gut microbiome correlates with plasma lipids in amyotrophic lateral sclerosis.
      Guo K, Figueroa-Romero C, Noureldein MH, Murdock BJ, Savelieff MG, Hur J, Goutman SA, Feldman EL. Brain, 2023 Sep 18; DOI:10.1093/brain/awad306
      PMID: 37721161
    • Presentation
      Interactions of the microbiome, metabolome, and immune system as underlying mechanisms of ALS pathogenesis
      Murdock B. 2023 Aug 29;
    • Presentation
      The Immune System in ALS: Sex, Drugs, and Demographics
      Murdock B. 2023 May 25;
    • Presentation
      The Immune System in ALS: Drugs and Demographics
      Murdock B. 2023 Apr 19;
    • Journal Article
      Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
      Stino AM, Bumma N, Smith R, Davalos L, Allen J, Ye JC, Pianko M, Campagnaro E, Fierro C, Awad A, Murdock B, Pietrzak M, Loszanski G, Kline DM, Efebera Y, Elsheikh B. Eur J Neurol, 2023 Nov 28; DOI:10.1111/ene.16164
      PMID: 38015467
    • Presentation
      The Immune System in ALS
      Murdock B. 2022 Sep 16;
    • Presentation
      Immune Changes Precede Clinical Changes in ALS
      Murdock B. 2022 Aug 25;
    • Presentation
      Tofacitinib as a Novel Therapeutic in C9 ALS mice
      Murdock B. 2022 May 4;